AstraZeneca
2025.09.12
13:58
AstraZeneca's long-acting C5 complement inhibitor Vilivo is launched in China
AstraZeneca announced the official launch of the long-acting C5 complement inhibitor Ultomiris (generic name: reslizumab injection) in China. It is indicated in combination with conventional therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive and neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin 4 (AQP4) antibody-positive. As a long-acting C5 complement inhibitor, reslizumab provides immediate, complete, and sustained inhibition of complement activation. It works by targeting the terminal complement C5 activation in the immune system. Reslizumab has recently been approved in China for the treatment of selected adult patients with gMG (April 2025) and NMOSD (August 2025). With the commercial launch of reslizumab in China, these patients will receive a long-acting complement inhibitor, potentially improving the quality of life of gMG patients and potentially bringing relapse-free outcomes to NMOSD patients.
2025.08.04
15:16
AstraZeneca's shares fell 0.6% in European trading.
2025.08.01
15:11
AstraZeneca's European shares fell 3%.
2025.07.29
22:17
AstraZeneca's chief financial officer: U.S. tariffs will not have a significant impact on the company; if there is any impact, it will be "very short-lived."
19:38
AstraZeneca CEO: Trump administration is considering its proposal to lower drug prices.
19:26
AstraZeneca CEO: US production will be fully localized within a few months.
19:23
AstraZeneca CEO: The company is almost self-sufficient in the United States.
19:22
AstraZeneca CEO: The US government has not promised the company can avoid tariffs.
19:21
AstraZeneca CEO: Europe is falling behind the United States and China.
19:20
AstraZeneca CEO: There is almost no innovation emerging in Europe.
19:18
AstraZeneca CEO: Meets with officials to discuss US drug production.
18:27
AstraZeneca's revenue in China reached US$3.515 billion in the first half of the year and will expand its presence in China
On July 29, AstraZeneca announced its results for the first half of 2025, achieving total revenue of $28.045 billion, an 11% year-on-year increase, including product revenue of $27.963 billion, an 11% year-on-year increase. By region, in the first half of the year, AstraZeneca's US market revenue reached $11.97 billion, a year-on-year increase of 12%, and its emerging market revenue reached $7.697 billion, a year-on-year increase of 12%. Revenue in China reached $3.515 billion, a year-on-year increase of 5%, accounting for over 12% of global revenue. "We are optimistic about China's innovation potential and will continue to expand our research and development presence in China," AstraZeneca disclosed. In March, the company announced a $2.5 billion investment plan in China, which included the establishment of its sixth global strategic research and development center in Beijing. Currently, two of AstraZeneca's six global strategic research and development centers are located in China.
2025.07.22
23:44
U.S. President Donald Trump praised AstraZeneca's (AZN.O) investments in the United States.
06:05
AstraZeneca (AZN.O): Plans to invest $50 billion in drug manufacturing and research and development in the United States.
2025.07.16
15:10
AstraZeneca shares fell 1% after Anselamimab failed to hit its main goal in a late-stage clinical trial.
Load More
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
Weekly Highlights
Musk: XAI will certainly raise funds in the next few months, but not now

2025-09-20

Nvidia (NVDA.O) fell further, dropping nearly 3%.

2025-09-17

SoftBank and OpenAI's AI joint venture in Japan is severely delayed, with an update now expected in November.

2025-09-18

Alipay's two operating entities have completed the name change

2025-09-19

Hande Information: The company has cooperation with Oracle

2025-09-23

ASIA TECH WIRE

Grasp technology trends

Download